co-presented by
ASSOCIATE SPONSORS
co-presented by
ASSOCIATE SPONSORS
Motilal Oswal is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 1940 in its research report dated January 31, 2026.
Sun Pharma Earnings: Sun Pharma’s operating performance also beat expectations. EBITDA came in at Rs 4,984.4 crore, higher than Street estimates of Rs 4,285 crore and up 23.4 per cent from Rs 4,009 crore a year ago.
Sun Pharma has engaged a European bank as an advisor to structure a comprehensive financial proposal that may be presented to Organon's board
The proposed transaction, which could be valued at about $10 billion including debt, would rank among the most ambitious moves by Sun’s billionaire founder Dilip Shanghvi
Sun Pharma’s focus areas involve investing in research and development (R&D) to further build its pipeline of innovative medicines.
'We continue to manufacture and supply approved products from the facility to the US market. We will work with the regulator to achieve fully compliant status,' the drug maker said.
Emkay Global Financial is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 2000 in its research report dated November 06, 2025.
Sun Pharma’s revenues from specialty drugs surpassed generic medicines for the first time in the US
Motilal Oswal is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 1960 in its research report dated November 06, 2025.
Despite macro uncertainties, Sun Pharma has been bullish on its specialty pipeline and global expansion.
While US generic sales would remain soft due to the reduced contribution of Revlimid, innovative medicine sales are expected to do well.
Revenue climbed 8.6% to Rs 14,405.2 crore, driven by double-digit growth in India, emerging markets, and rest of world (RoW) geographies.
Sun Pharma Executive Chairman Dilip Shanghvi said the company remains on track to launch UNLOXCYT, an FDA-approved treatment for advanced skin cancer, in the US in the second half of FY26
New Delhi, Nov 5 Sun Pharmaceutical Industries on Wednesday posted a 2.56 per cent increase in its consolidated net profit to Rs 3,118 crore for the sec..
With gRevlimid exclusivity nearing its end, the spotlight shifts to Sun Pharma’s specialty launches, domestic growth resilience, and management’s outlook on profitability for the second half of FY26.
The move is part of a broader push to onshore pharmaceutical production and reduce reliance on foreign suppliers, particularly from India and China.
Imported generics have so far managed to escape Trump’s glare likely due to their critical role in keeping US healthcare costs in check. However, Indian pharma is not waiting for the axe to fall, and experts say a multi-pronged defence strategy by key players is already in motion.
The diktat could be positive for local generic drug companies
Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 1960 in its research report dated September 23, 2025.
Exports from Halol manufacturing plant continue to be restricted
The US government has long sought to shift pharmaceutical manufacturing back to domestic soil, citing both economic and national security concerns.
Motilal Oswal is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 1960 in its research report dated July 31, 2025.
